Evaluating year-to-year anomalies in tropical wetland methane emissions using satellite CH₄ observations

Natural wetlands are the largest source of methane emissions, contributing 20–40% of global emissions and dominating the inter-annual variability. Large uncertainties remain on their variability and response to climate change. This study uses atmospheric methane observations from the GOSAT satellite to evaluate methane wetland emission estimates. We assess how well simulations reproduce the observed methane inter-annual variability by evaluating the detrended seasonal cycle. The latitudinal means agree well but maximum differences in the tropics of 28.1–34.8 ppb suggest that all simulations fail to capture the extent of the tropical wetland seasonal cycle. We focus further analysis on the major natural wetlands in South America: the seasonally flooded savannah of the Pantanal (Brazil) and Llanos de Moxos (Bolivia) regions; and the riverine wetlands formed by the Paraná River (Argentina). We see large discrepancies between simulation and observation over the Pantanal and Llanos de Moxos region in 2010, 2011 and 2014 and over the Paraná River region in 2010 and 2014. We find highly consistent behaviour between the time and location of these methane anomalies and the change in wetland extent, driven by precipitation related to El Niño Southern Oscillation activity. We conclude that the inability of land surface models to increase wetland extent through overbank inundation is the primary cause of these observed discrepancies and can lead to under-estimation of methane fluxes by as much as 50% (5.3–11.8 Tg yr −1 ) of the observed emissions for the combined Pantanal and Paraná regions. As the hydrology of these regions is heavily linked to ENSO variability, being able to reproduce changes in wetland behaviour is important for successfully predicting their methane emissions

Comparison of the HadGEM2 climate-chemistry model against in situ and SCIAMACHY atmospheric methane data

Wetlands are a major emission source of methane (CH₄) globally. In this study, we evaluate wetland emission estimates derived using the UK community land surface model (JULES, the Joint UK Land Earth Simulator) against atmospheric observations of methane, including, for the first time, total methane columns derived from the SCIAMACHY instrument on board the ENVISAT satellite. Two JULES wetland emission estimates are investigated: (a) from an offline run driven with Climatic Research Unit–National Centers for Environmental Prediction (CRU-NCEP) meteorological data and (b) from the same offline run in which the modelled wetland fractions are replaced with those derived from the Global Inundation Extent from Multi-Satellites (GIEMS) remote sensing product. The mean annual emission assumed for each inventory (181 Tg CH₄ per annum over the period 1999–2007) is in line with other recently published estimates. There are regional differences as the unconstrained JULES inventory gives significantly higher emissions in the Amazon (by ~36 Tg CH₄ yr¯¹) and lower emissions in other regions (by up to 10 Tg CH₄ yr¯¹) compared to the JULES estimates constrained with the GIEMS product. Using the UK Hadley Centre's Earth System model with atmospheric chemistry (HadGEM2), we evaluate these JULES wetland emissions against atmospheric observations of methane. We obtain improved agreement with the surface concentration measurements, especially at high northern latitudes, compared to previous HadGEM2 runs using the wetland emission data set of Fung et al. (1991). Although the modelled monthly atmospheric methane columns reproduce the large-scale patterns in the SCIAMACHY observations, they are biased low by 50 part per billion by volume (ppb). Replacing the HadGEM2 modelled concentrations above 300 hPa with HALOE–ACE assimilated TOMCAT output results in a significantly better agreement with the SCIAMACHY observations. The use of the GIEMS product to constrain the JULES-derived wetland fraction improves the representation of the wetland emissions in JULES and gives a good description of the seasonality observed at surface sites influenced by wetlands, especially at high latitudes. We find that the annual cycles observed in the SCIAMACHY measurements and at many of the surface sites influenced by non-wetland sources cannot be reproduced in these HadGEM2 runs. This suggests that the emissions over certain regions (e.g. India and China) are possibly too high and/or the monthly emission patterns for specific sectors are incorrect. The comparisons presented in this paper show that the performance of the JULES wetland scheme is comparable to that of other process-based land surface models. We identify areas for improvement in this and the atmospheric chemistry components of the HadGEM Earth System model. The Earth Observation data sets used here will be of continued value in future evaluations of JULES and the HadGEM family of models

Importance of including soil moisture in drought monitoring over the Brazilian semiarid region: An evaluation using the JULES model, in situ observations, and remote sensing

Soil moisture information is essential to monitoring of the intensity of droughts, the start of the rainy season, planting dates and early warnings of yield losses. We assess spatial and temporal trends of drought over the Brazilian semiarid region by combining soil moisture observations from 360 stations, root zone soil moisture from a leading land surface model, and a vegetation health index from remote sensing. The soil moisture dataset was obtained from the network of stations maintained by the National Center of Monitoring and Early Warning of Natural Disasters (Cemaden), in Brazil. Soil water content at 10 to 35 cm depth, for the period 1979–2018, was obtained from running the JULES land surface model (the Joint UK Land Environment Simulator). The modelled soil moisture was correlated with measurements in the common period of 2015–2018, resulting in an average correlation coefficient of 0.48 across the domain. The standardized soil moisture anomaly (SMA) was calculated for the long-term modelled soil moisture and revealed strong negative values during well-known drought periods in the region, especially during El-Niño years. The performance of SMA in identifying droughts during the first 2 months of the raining and cropping season was similar to the Standardized Precipitation Index (SPI), commonly used for drought assessment: 12–14 events were identified by both indices. Finally, the temporal relationship between both SMA and SPI with the Vegetation Health Index (VHI) was assessed using the cross-wavelet transform. The results indicated lagged correlations of 1 to 1.5 months in the annual scale, suggesting that negative trends in SMA and SPI can be an early warning to yield losses during the growing season. Public policies on drought assessment should consider the combination of multiple drought indices, including soil moisture anomaly

Interactions between microenvironment and cancer cells in two animal models of bone metastasis

The preferential proliferation of cancer cells in the bone microenvironment is poorly characterised. Expression pattern of bone marrow and other organ microenvironment in contact with osteolytic (Walker W256) and osteoblastic (MatLyLu MLL) metastases were investigated. Fisher and Copenhagen rats received, respectively, W256 and MLL cells injection. Bone and soft tissues were analysed by immunochemistry for DKK1, cathepsin K, RANKL, MCSF or IL6 expression. Tartrate-resistant acid phosphatase (TRAcP)-positive cells were detected by a histoenzymatic technique. In bone, expressions of MCSF and DKK1 were shown in stromal cells of the bone marrow, in contact with metastatic foci of both tumours. Many stromal cells were found RANKL positive in the vicinity of the tumours. Cells expressing cathepsin K and multinucleated TRAcP+ cells were found in direct contact with trabeculae but also in bone marrow spaces near metastatic cells. In extraosseous tumours, cells in contact with malignant cells did not expressed DKK1, MCSF, cathepsin K and IL6. Some RANKL+ cells were found in the periphery of subcutaneous tumours but may represent Langerhans cells. Abnormal presence of TRAcP+ cells was never observed in the vicinity of malignant cells. Interaction between stromal and cancer cells induces the expression on the formers of characteristics leading to osteoclastogenesis only in the bone microenvironment

Measurement of the 13 C isotopic signature of methane emissions from Northern European wetlands

Isotopic data provide powerful constraints on regional and global methane emissions and their source profiles. However, inverse modeling of spatially-resolved methane flux is currently constrained by a lack of information on the variability of source isotopic signatures. In this study, isotopic signatures of emissions in the Fennoscandian Arctic have been determined in chambers over wetland, in the air 0.3 to 3 m above the wetland surface and by aircraft sampling from 100 m above wetlands up to the stratosphere. Overall the methane flux to atmosphere has a coherent δ13C isotopic signature of -71 ± 1‰, measured in situ on the ground in wetlands. This is in close agreement with δ13C isotopic signatures of local and regional methane increments measured by aircraft campaigns flying through air masses containing elevated methane mole fractions. In contrast results from wetlands in Canadian boreal forest further south gave isotopic signatures of -67 ± 1 ‰. Wetland emissions dominate the local methane source measured over the European Arctic in summer. Chamber measurements demonstrate a highly variably methane flux and isotopic signature, but the results from air sampling within wetland areas show that emissions mix rapidly immediately above the wetland surface and methane emissions reaching the wider atmosphere do indeed have strongly coherent C isotope signatures. The study suggests that for boreal wetlands (>60°N) global and regional modeling can use an isotopic signature of -71‰ to apportion sources more accurately, but there is much need for further measurements over other wetlands regions to verify this.UK Natural Environment Research Council (NERC). Grant Numbers: NE/I028874/1, NE/I014683/1, NE/F020937/1 European Community's Seventh Framework Programme. Grant Number: FP7/2007‐2013 InGOS. Grant Number: 28427

A Functional Henipavirus Envelope Glycoprotein Pseudotyped Lentivirus Assay System

<p>Abstract</p> <p>Background</p> <p>Hendra virus (HeV) and Nipah virus (NiV) are newly emerged zoonotic paramyxoviruses discovered during outbreaks in Queensland, Australia in 1994 and peninsular Malaysia in 1998/9 respectively and classified within the new <it>Henipavirus </it>genus. Both viruses can infect a broad range of mammalian species causing severe and often-lethal disease in humans and animals, and repeated outbreaks continue to occur. Extensive laboratory studies on the host cell infection stage of HeV and NiV and the roles of their envelope glycoproteins have been hampered by their highly pathogenic nature and restriction to biosafety level-4 (BSL-4) containment. To circumvent this problem, we have developed a henipavirus envelope glycoprotein pseudotyped lentivirus assay system using either a luciferase gene or green fluorescent protein (GFP) gene encoding human immunodeficiency virus type-1 (HIV-1) genome in conjunction with the HeV and NiV fusion (F) and attachment (G) glycoproteins.</p> <p>Results</p> <p>Functional retrovirus particles pseudotyped with henipavirus F and G glycoproteins displayed proper target cell tropism and entry and infection was dependent on the presence of the HeV and NiV receptors ephrinB2 or B3 on target cells. The functional specificity of the assay was confirmed by the lack of reporter-gene signals when particles bearing either only the F or only G glycoprotein were prepared and assayed. Virus entry could be specifically blocked when infection was carried out in the presence of a fusion inhibiting C-terminal heptad (HR-2) peptide, a well-characterized, cross-reactive, neutralizing human mAb specific for the henipavirus G glycoprotein, and soluble ephrinB2 and B3 receptors. In addition, the utility of the assay was also demonstrated by an examination of the influence of the cytoplasmic tail of F in its fusion activity and incorporation into pseudotyped virus particles by generating and testing a panel of truncation mutants of NiV and HeV F.</p> <p>Conclusions</p> <p>Together, these results demonstrate that a specific henipavirus entry assay has been developed using NiV or HeV F and G glycoprotein pseudotyped reporter-gene encoding retrovirus particles. This assay can be conducted safely under BSL-2 conditions and will be a useful tool for measuring henipavirus entry and studying F and G glycoprotein function in the context of virus entry, as well as in assaying and characterizing neutralizing antibodies and virus entry inhibitors.</p

Влияние фосфатных связующих на физико-механические свойства периклазохромитовых огнеупоров

У данній статті наведено та порівняно фізико-механічні властивості периклазо-хромітових матеріалів в залежності від різних типів фосфатних зв’язуючих та введення різних домішок. Визначено, що найбільш раціональним є введення триполіфосфату натрію.In given clause are resulted and the physycal-mechanical properties periclase-cgromite of materials are compared depending on different of types phosphate binding and introduction of the various additives. Is determined, that most rational is the introduction treepolyphosphate sodume

More rapid polar ozone depletion through the reaction of HOCI with HCI on polar stratospheric clouds

THE direct reaction of HOC1 with HC1, known to occur in liquid water1 and on glass surfaces2, has now been measured on surfaces similar to polar stratospheric clouds3,4 and is shown here to play a critical part in polar ozone loss. Two keys to understanding the chemistry of the Antarctic ozone hole5-7 are, one, the recognition that reactions on polar stratospheric clouds transform HC1 into more reactive species denoted by ClOx(refs 812) and, two, the discovery of the ClO-dimer (C12O2) mechanism that rapidly catalyses destruction of O3(refs 1315). Observations of high levels of OClO and ClO in the springtime Antarctic stratosphere1619 confirm that most of the available chlorine is in the form of ClOx (refs 20, 21). But current photochemical models22,23 have difficulty converting HC1 to ClOx rapidly enough in early spring to account fully for the observations5-7,20,21. Here I show, using a chemical model, that the direct reaction of HOC1 with HC1 provides the missing mechanism. As alternative sources of nitrogen-containing oxidants, such as N2O5 and ClONO2, have been converted in the late autumn to inactive HNO3 by known reactions on the sulphate-layer aerosols24-27, the reaction of HOC1 with HC1 on polar stratospheric clouds becomes the most important pathway for releasing that stratospheric chlorine which goes into polar night as HC1. © 1992 Nature Publishing Group

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention